Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review

ROS1 rearrangement occurs in 1–2% of non‐small cell lung cancer (NSCLC) cases. These patients would benefit from treatment with the anaplastic lymphoma kinase inhibitor, crizotinib; however, resistance to crizotinib inevitably develops in such patients despite an initial response. The mechanism of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chun‐wei, Wang, Wen‐xian, Huang, Rong‐fang, He, Cheng, Liao, Xing‐hui, Zhu, You‐cai, Du, Kai‐qi, Zhuang, Wu, Chen, Yan‐ping, Chen, Gang, Fang, Mei‐yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668514/
https://www.ncbi.nlm.nih.gov/pubmed/28845578
http://dx.doi.org/10.1111/1759-7714.12496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668514/
https://www.ncbi.nlm.nih.gov/pubmed/28845578
http://dx.doi.org/10.1111/1759-7714.12496

Ejemplares similares